Xeris Biopharma Holdings Inc. Stock
Xeris Biopharma Holdings Inc. gained 2.570% today.
Xeris Biopharma Holdings Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 8 € there is a hugely positive potential of 60.06% for Xeris Biopharma Holdings Inc. compared to the current price of 5.0 €.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 2.570% | -2.383% | -17.593% | 18.830% | -20.855% | 291.939% | 37.308% |
| Heron Therapeutics Inc. | 0.520% | -14.077% | -20.289% | -58.236% | -23.294% | -57.823% | -94.153% |
| Evolus Inc | -0.880% | 27.778% | 25.683% | -60.000% | -15.596% | -40.645% | -54.747% |
| Sangamo Therapeutics Inc. | 2.190% | 5.951% | 7.909% | -61.436% | 1.801% | -83.348% | -96.276% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat